Valuation

RVMDREVOLUTION Medicines Inc

StockNasdaqUnited StatesHealth careEU retail investors: available

−6.4% today · +182.0% over a year

1/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 20% of the instruments we score

Trend: among the best of its peers; Quality: among the weakest; priced higher than most peers. No dividend.

REVOLUTION Medicines Inc (RVMD) valuation against sector peers: P/B 16.3, free-cash-flow yield −3.7%, P/S 154.7.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricRVMDSector medianvs median
P/E—30.9 · n=158—
P/B16.34.1 · n=307302% above
P/S154.74.1 · n=3023,705% above
EV/EBIT—26.0 · n=146—
Free-cash-flow yield−3.7%1.3% · n=291377% below
Dividend yield0.00%0.00% · n=362—
Return on equity−93.6%−2.4% · n=308—
Return on invested capital−74.1%0.6% · n=28211,599% below
Gross margin—63.3% · n=205—
Net debt / EBITDA—1.27 · n=151—

Value factor: 17 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

LLYEli Lilly & Co49.033.6—1.5%0.6%6/10
JNJJohnson & Johnson41.98.3—3.1%1.9%8/10
ABBVAbbVie50.6—27.93.6%2.9%6/10
MRKMerck147.98.1—4.1%2.3%8/10
UNHUnitedHealth22.73.517.36.3%2.2%10/10
TMOThermo Fisher Scientific37.64.935.52.9%0.3%9/10
AMGNAmgen27.017.623.33.8%2.1%8/10
GILDGilead Sciences—16.1—6.5%1.9%5/10
ABTAbbott40.33.732.63.6%2.8%6/10
PFEPfizer41.61.9—7.0%7.3%1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 04 Nov 2026